Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Cash and Equivalents of $373.69 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $373.69M | +1111.3% |
| 2024 | $30.85M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $408.74M | — | +1224.9% |
| December 31, 2024 | $30.85M | — | +1573.4% |
| March 31, 2024 | $1.84M | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +1111.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, BridgeBio Oncology Therapeutics, Inc.’s cash and equivalents has grown by 1111.3% (from $30.85 million to $373.69 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: